【摘 要】
：
We report here the therapeutic efficacy of tumor-targeting Ginsenoside Rg3 immune-nanoemulsion mediated by VEGFR-3 (VRIN) on nude mouse models of gastric cancer.Orthotopic nude mouse model of gastric
【机 构】
：
Clinical Traditional Chinese Medical College,Yangzhou University, 11 Huaihai Road,Yangzhou,Jiangsu P
论文部分内容阅读
We report here the therapeutic efficacy of tumor-targeting Ginsenoside Rg3 immune-nanoemulsion mediated by VEGFR-3 (VRIN) on nude mouse models of gastric cancer.Orthotopic nude mouse model of gastric cancer was made with the human gastric cancer cell line NUGC-4 epressing RFP.After tumor implantation, the nude mice were treated with VRIN, 5-FU, and salin, i.v..Fluorescence images were subjected to mice to real-time evaluate the tumor growth in vivo.After treatment 30 days, allmice were necropsied for tumor removal and measurement.The mean weight of tumor in the mice treated with VRIN, 5-FU, and salin was 0.58±0.21, 0.66±0.25, and 2.14±0.86 g respectively.The lymph node metastasis of tumor was assessed at the same time.The metastasis rate was 12.5% (1/8), 50% (4/8), and 87.5% (7/8) respectively.There was a significant difference between VRIN and salin group in tumor weight (P<0.001) and in the metastasis rate (P=0.01).We also detected the expression ofVEGF-C mRNA and protein in the tumors in VRIN,5-FU, and salin groups and found that a significant difference was between VRIN and salin group (P=0.002).Our data demonstrate that VRIN is effective for target treatment of human gastric cancer and suggest its clinical potential for treatment of gastric cancer.
其他文献
目的：探讨扶正抗癌方抑制H1650细胞增殖的分子机制.方法：四甲基偶氮唑盐(MTT)比色法检测H1650细胞的增殖;Annexin V-FITC/碘化丙啶(PI)流式细胞术检测H1650细胞的凋亡;半胱氨酸蛋白酶3/7(Caspase3/7)活力检测试剂盒检测Caspase-3/7的活力;蛋白质印迹法检测proCasspase-3、磷酸化应激活化蛋白激酶/c-Jun氨基末端激酶(p-SAPK/JN
目的：探讨扶正抗癌方对TKIs治疗EGFR基因非突变的晚期NSCLC的增敏作用.方法：纳入EGFR基因野生型的ⅢB/Ⅳ期NSCLC70例,治疗组35例予扶正抗癌方联合TKIs治疗,对照组35例予扶正抗癌方联合化疗治疗,观察对比两组PFS及DCR等指标.结果：治疗组中,ORR为8.82％,DCR为64.70％.对照组中,ORR为24.24％,DCR为72.73％,两者差异均无统计学意义(P＞0.05
目的：探讨扶正抗癌方增敏吉非替尼抑制肺癌作用的分子机制.方法：MTS法检测肺癌细胞经药物处理后的细胞活性;流式细胞术(碘化丙啶PI染色)检测肺癌细胞经药物处理后的细胞周期变化;蛋白质印迹法检测p-Akt、Akt、p65、p50和MUC1蛋白的表达水平;实时荧光定量PCR(qRT-PCR)检测MUC1在mRNA水平的表达;瞬时转染过表达Akt、p65和MUC1在肺癌细胞中的表达水平;裸鼠成瘤实验及生
目的：探讨扶正抗癌方抑制肺癌细胞转移的分子机制.方法：MTT法检测肺癌细胞经扶正抗癌方处理后的细胞活性;细胞划痕实验检测扶正抗癌方对肺癌细胞迁移能力的影响;Transwell小室法细胞迁移实验检测扶正抗癌方对肺癌细胞迁移能力的作用;Transwell小室法细胞侵袭实验检测扶正抗癌方对肺癌细胞侵袭能力的影响;MMP9活力实验检测扶正抗癌方处理后肺癌细胞中MMP9活力的变化;蛋白质印迹法检测MMP9、
目的：观察肺瘤平膏及其拆方对小鼠骨髓来源树突状细胞中CCR7介导的PI3K/AKT通路表达的影响.方法：建立小鼠骨髓来源树突状细胞模型,分别加入肺瘤平膏及其拆方含药血清进行干预,应用Transwell趋化实验、免疫荧光和western blot等方法,检测CCR7、PI3K、AKT各蛋白表达.结果：Transwell结果显示,与阴性空白对照组相比较,各组肺瘤平膏及其拆方含药血清均能增加BMDCs过
目的：观察升血颗粒(PG)含药血清对人白血病细胞K562/ADR多药耐药性的逆转作用,并探讨其逆转机制.方法：采用MTT法测定细胞的药敏性及耐药逆转性,应用流式细胞仪检测非细胞毒性的含药血清处理后K562/ADR细胞细胞内阿霉素(ADM)的浓度.结果：低、中、高剂量含药血清对K562/ADR细胞无明显细胞毒性.低、中、高剂量含药血清作用后,ADM对K562/ADR细胞的半数抑制浓度(IC50)显著
目的：探讨西黄丸抑制胃癌及其肿瘤血管生成拟态形成的相关分子机制.方法：通过通过GFP细胞转染、细胞三维培养等模型,运用RT-qPCR、Western-blot、IHC,建立人胃癌MGC803细胞体内体外、乏氧常氧等不同状态下VM形成模型,检测VM形成关键因子VE-Cadherin、EphA2、MMP-2等的表达,并通过高通量基因芯片筛选进一步明确西黄丸抗肿瘤的作用靶点.结果：西黄丸可以抑制胃癌细胞
慈丹胶囊是传统中药配方,作为一种抗肿瘤药物己被医用10年以上.在此次研究中,探索了慈丹胶囊对肝细胞癌的抗肿瘤作用及其分子机制.共有372名在上海东方肝胆外科医院和北京市伟达中医肿瘤医院确诊为原发性肝细胞癌的患者参加了研究.其中,共有92例患者在手术后三个月内服用慈丹胶囊,另280例成为对照组.为了对慈丹胶囊的疗效进行分析,进行了相关的症状监测以及肝功能检查,包括测量甲胎蛋白、αL岩藻糖苷酶、碱性磷
目的：探讨健脾疏肝解毒中药增强MDA-MB231三阴性乳腺癌细胞对化疗药物顺铂(DDP)敏感性的机理.方法：利用三阴性乳腺癌细胞MDA-MB231为细胞模型,分别用5％、10％、20％中药血清和对照血清培养细胞,同时加入10μg/ml顺铂,处理72小时后,采用MTT比色法检测不同浓度的中药对MDA-MB231三阴性乳腺癌细胞抑制率的影响.结果：用10％和20％的中药血清处理细胞后,能显著提高细胞对
Qigesan (QGS), a well-known traditional Chinese medicinal formula, has long been used to treat patients with esophageal cancer.However, the anticancer mechanisms of action of QGS remain unknown.This s